In patients with low tumor PLK5 mRNA expression, the median (95% CI) OS was 49.0 (39.1–58.9) months; the 3-year and 5-year OS rates were 74.1% and 35.7%, respectively, in NSCLC patients (Table 6). This evidence concerns the gene PLK5 and non-small cell lung carcinoma.